ArticleNature biotechnology2026
Inducing bacterial calcification for systematic treatment and immunomodulation against methicillin-resistant Staphylococcus aureus.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Osteomyelitis: Epidemiology, Classification, Pathophysiology, Clinical Features, Diagnosis, and Management.MedComm · 2026Review
- NIR-Assisted Multimodal Strategies for Enhanced Antibacterial Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Dual-Modal Phototherapeutic Nanoagents Eradicating Drug-Resistant Bacteria via Multi-Pathway of Membrane Disruption, Oxidative Damage, and Energy Metabolism Interference.Advanced healthcare materials · 2026Article
- Iron-Hijacking Trojan Horse Nanoplatform Combats Implant-Associated Biofilm Infections Through Immuno-Fibrotic Remodeling.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Acid-Triggered, Enzyme-Enabled EPS-Degrading Nanoplatform With Enhanced In Situ Retention for Intravenous Biofilm Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Calcium-based biomineralisation remodels the pathogen-host interface.Clinical and translational medicine · 2026Article
- Aptamer-guided upconversion nanoconstructs enable proximity-dependent and precise photodynamic therapy for MRSA-infected wounds.Materials today. Bio · 2026Article
- Multi-enzymatic catalysis copper ceria-polyphenol nanozyme for balancing peroxidase catalysis and reactive oxygen scavenging: a synergistic strategy for enhancing drug-resistant bacteria eradication.Journal of nanobiotechnology · 2026Article
- Performance of gradient diffusion strip and disk diffusion versus broth microdilution for lefamulin susceptibility testing of 422Journal of clinical microbiology · 2026Article
- Proanthocyanidins inhibit methicillin-resistantCurrent research in food science · 2026Article
- Copper tannic acid coordination nanosheet as a potent in-situ antibiotic sustained-release carrier for chronic osteomyelitis.Journal of materials science. Materials in medicine · 2025Article
- Novel Therapies for Prosthetic Joint Infections Caused by Methicillin-ResistantPathogens (Basel, Switzerland) · 2025Review
- A novel therapeutic strategy of methicillin-resistantEngineering microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) has become one of the deadliest bacteria globally due to antibiotic resistance. In this study, we crosslinked antigen-binding fragments of monoclonal antibodies against the wall-teichoic acid of S. aureus with polysialic acid to form an antibody‒PSA conjugate, which can effectively target and induce calcification on the surface of MRSA. This process eliminates bacteria by hindering the energy metabolism and multiple essential metabolic pathways of MRSA. We found that bacterial calcification leads to increased expression of calprotectin, S100A8/S100A9, in macrophages and monocytes in vivo and can stimulate the activation of macrophages to an inflammatory state, thereby promoting bacterial eradication as an immunomodulator. Systemic administration of the antibody‒PSA conjugate demonstrates high efficacy and safety for treating chronic lung infections and chronic osteomyelitis caused by MRSA in mice. This study offers a promising therapy for treating drug-resistant bacteria and related refractory pathogenic infections.
Indexed as
Identifiers
40664980What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.